AI Article Synopsis
- [Zr]Oxinate is a PET tracer designed for imaging and understanding cell movement in diseases; however, there’s been no previous data on its production for human applications.
- The report details the production process of [Zr]Oxinate in compliance with specific USP standards, demonstrating that the final product has high radiochemical purity and stability, making it suitable for clinical use.
- Testing showed that [Zr]Oxinate doesn't harm white blood cell viability and can be used to label various cell types, potentially enhancing our understanding of disease mechanisms in human patients.
Article Abstract
[ Zr]Oxinate is a Positron Emission Tomography (PET) tracer for cell radiolabeling that can enable imaging techniques to help better understand cell trafficking in various diseases. Although several groups have synthetized this compound for use in preclinical studies, there is no available data regarding the production of [ Zr]Oxinate for human use. In this report, we describe the detailed production of [ Zr]Oxinate under USP <823> and autologous leukocyte radiolabeling under USP <797>. The final product presented high radiochemical purity and stability at 24 h post synthesis (>99%) and passed in all quality control assays required for clinical use. [ Zr]Oxinate did not compromise the white blood cells viability and did not show considerable cellular efflux up to 3 h post labeling. The translation of this technique into human use can provide insight into several disease mechanisms since [ Zr]Oxinate has the potential to label any cell subset of interest.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jlcr.3901 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!